Analysis Cannabics Pharmaceuticals Inc. (CNBX)
5/29/2024
Analysis of Cannabics Pharmaceuticals Inc. (CNBX)
Cannabics Pharmaceuticals Inc. (CNBX) is currently trading at $0.01. The Relative Strength Index (RSI) indicator is around 46.32, indicating a neutral position. The Moving Average Convergence Divergence (MACD) indicator is slightly negative at -0.00017, with the signal line at -0.00023. The MACD histogram is positive at 0.00006.In terms of moving averages, the Simple Moving Average (SMA) is at $0.01004, the Exponential Moving Average (EMA) is at $0.01026, and the Weighted Moving Average (WMA) is at $0.01002.
Overall, based on the indicators and moving averages, the stock seems to be in a relatively stable position with no strong bullish or bearish signals at the moment. It would be important to monitor any significant changes in these indicators to make informed investment decisions.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company over the specified periods.
Growth estimates
Based on the consensus estimates provided:- The current year growth rate is 7.5%
- The next quarter growth rate is 4.8%
- The current quarter growth rate is 5.6%
- The next year growth rate is 9.7%
- The next 5 years compound annual growth rate (CAGR) is 11%
- The past 5 years compound annual growth rate (CAGR) is 20.15%
It can be observed that the growth rates are expected to vary across different time periods. The company is projected to experience a higher growth rate in the next 5 years compared to the current year and next quarter. Additionally, the past 5 years have seen a significantly higher growth rate compared to the projections for the future periods. This information can be valuable for investors and stakeholders in assessing the future performance and potential of the company.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the current price is below both the average and median predicted prices. The analysts' opinions vary, with a wide range between the low and high estimates. The median price of $200 could be considered a benchmark for the future price.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous results were reported on February 27, 2025, but the details were not disclosed. Before that, on January 31, 2025, the results were released after hours. The results from October 31, 2024, were not provided at the time. However, on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits for a specific company.In terms of financials, the company has a strong operating cash flow and levered free cash flow. The balance sheet shows a healthy current ratio, but a relatively high total debt to equity ratio. The profit margin and operating margin are both positive, indicating profitability. The company's return on assets and return on equity are also positive.
Moving on to stock statistics, the short ratio is relatively low, and the percentage held by institutions is significant. The stock price summary shows the beta, moving averages, and the range of the stock price over the past year.
Valuation metrics indicate the company's price-to-earnings ratios, price-to-book ratio, price-to-sales ratio, and other valuation measures. The market capitalization and enterprise value are also provided.
Lastly, the dividends and splits section includes information on dividend rates, dividend yields, dividend dates, and historical stock splits for the company.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite fluctuations in other financial metrics, the gross profit has generally followed the trend of increasing sales revenue.
3. The company has been able to maintain a healthy EBITDA margin, with EBITDA reaching $129.2 billion in 2023.
4. Net income has also shown an increasing trend, reaching $97 billion in 2023 from $57.4 billion in 2020.
5. Earnings per share (EPS) have been relatively stable over the years, with slight fluctuations but no significant downward trends.
6. The company has managed its operating expenses effectively, with operating income consistently growing over the years.
7. Despite variations in non-operating interests and other income/expenses, the company has been able to sustain its profitability and financial performance.
8. The number of basic and diluted shares outstanding has remained relatively stable over the years.
Overall, the company has demonstrated a strong revenue growth trajectory, effective cost management, and consistent profitability.
Balance Sheet
These are balance sheets. Here are the conclusions based on the data provided:1. The total assets have been increasing over the years, reaching the highest value of $365,725,000,000 in 2018.
2. Current assets fluctuate from year to year, with the highest value recorded in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, with the highest value of $234,386,000,000 in 2018.
4. Total liabilities have also been increasing, reaching the highest value of $290,437,000,000 in 2023.
5. Shareholders' equity has shown fluctuations over the years, with the highest value of $107,147,000,000 in 2018.
6. The company has been relying more on non-current assets to finance its operations, as seen in the increasing trend of non-current assets compared to current assets.
7. The company has been taking on more debt over the years, as indicated by the increasing trend in total liabilities.
8. The fluctuations in shareholders' equity suggest varying profitability or capital injections into the company.
9. The company seems to have a stable cash position, with fluctuations in cash and cash equivalents over the years.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing, indicating improved operational efficiency.
3. Financing activities show significant fluctuations, especially in terms of common stock repurchase and long-term debt issuance.
4. Investing activities also vary, with notable amounts spent on the sale and purchase of investments.
5. The end cash position has been relatively stable, with a slight decrease in 2022 compared to 2021.
6. Interest paid has increased over the years, which could indicate higher debt levels or interest rates.
7. Income tax paid has also fluctuated, possibly due to changes in profitability or tax regulations.
8. Stock-based compensation has been a consistent expense, reflecting the company's use of equity incentives.
9. The company has been paying dividends regularly, with varying amounts each year.
10. Overall, the cash flow statement provides insights into the company's financial health, liquidity, and capital allocation strategies.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.33, which is higher than the EPS of $1.26 from the same quarter a year ago. The range of estimates is between $1.27 and $1.36, as provided by 26 analysts.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.53, compared to $1.46 from the previous year. The estimates range from $1.44 to $1.63, based on 25 analysts' forecasts.
3. Looking at the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.59, an increase from the previous year's EPS of $6.13. The analysts' estimates range from $6.43 to $6.92, with insights from 39 analysts.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is $7.23, with a range of estimates between $6.40 and $7.90. This forecast is based on inputs from 39 analysts.
Overall, the analysts are predicting growth in earnings per share both for the upcoming quarters and the next fiscal years, indicating positive expectations for the company's performance.
MACD of CNBX
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
